| Recruiting | N/A | 800 | RoW | | UNC Lineberger Comprehensive Cancer Center, National Institutes of Health (NIH), Fogarty International Center of the National Institute of Health | Lymphoma, Hematologic Malignancies | 01/30 | 01/30 | | |
NCT04585893: Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi |
|
|
| Active, not recruiting | 2 | 15 | RoW | Rituximab, Rituxan, Etoposide, Toposar, VP-16 | UNC Lineberger Comprehensive Cancer Center, Fogarty International Center of the National Institute of Health | Multicentric Castleman Disease | 08/25 | 06/27 | | |
| Recruiting | N/A | 180 | RoW | standard of care chemotherapy | UNC Lineberger Comprehensive Cancer Center, National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI) | Kaposi Sarcoma, HIV | 06/27 | 06/27 | | |